Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > Peanut gallery
View:
Post by TeeveePoor on Mar 10, 2010 12:34am

Peanut gallery

Nice to see that Teevee has been drawn in from the peanut gallery again! 
It's good to know that his extremely bearish perspective from a level below 15 cents, has not been abandoned yet.  As I recall, in his expert opinion, ISA was to drift lower from the mid teen level, as the company ran out of cash and was delisted from the exchanges where it remains at present. With what can now only be days remaining in the company's existence, it's probably well worth me posting $2.50 per share to short at 40 cents. It will certainly result in a very good annualized return, but my worst nightmare is still a nagging concern that TeeVee will again become a bull on me at stock prices above the $2.00 level :-)
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities